Get the Stockscreener App
6.08
3.93%
0.23
After Hours:
6.08
Entrada Therapeutics Inc stock is traded at $6.08, with a volume of 446.75K.
It is up +3.93% in the last 24 hours and down -21.45% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$5.85
Open:
$5.95
24h Volume:
446.75K
Relative Volume:
0.99
Market Cap:
$236.03M
Revenue:
$5.74M
Net Income/Loss:
$-166.12M
P/E Ratio:
-1.5208
EPS:
-3.9978
Net Cash Flow:
$-131.64M
1W Performance:
-4.10%
1M Performance:
-21.45%
6M Performance:
-44.73%
1Y Performance:
-7.03%
1-Day Range:
$5.95
$6.23
1-Week Range:
$5.75
$6.55
52-Week Range:
$4.93
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
6.08 | 227.10M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
View All
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Entrada Therapeutics Inc (TRDA) Cash Flow - TradingKey
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Balance Sheet - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why (TRDA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Entrada Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Mild Stock UptickBanking Earnings Report - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates - MSN
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Entrada Therapeutics (TRDA) Gains 4.6% as Biotech Stock Tests Key Resistance Near $7.47Bullish Sentiment - dars.gov.et
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
Entrada Therapeutics (TRDA) Slips 4.5% as Stock Tests Key Support ZoneInvestment Factor - dars.gov.et
Entrada Therapeutics, Inc.(NasdaqGM: TRDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Understanding Momentum Shifts in (TRDA) - Stock Traders Daily
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Enterprise value to revenue forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView
TRDA Forecast — Price Target — Prediction for 2027 - TradingView
Entrada Therapeutics (TRDA) Declines Nearly 5% as Stock Tests Key Support at $6.81Earnings Quality Factor - dars.gov.et
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Entrada Therapeutics (TRDA) Surges 4.11% as Shares Test Resistance Near $7.44Liquidity Sweep - dars.gov.et
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) director receives grant of 19,000 stock options - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - The Globe and Mail
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Entrada Therapeutics (TRDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Entrada Therapeutics Inc. (TRDA) Faces Selling Pressure as Shares Dip to $6.20Triple Top - dars.gov.et
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA) - The Globe and Mail
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):